Anika Therapeutics, Inc., a leader in products for tissue protection, healing, and repair based on hyaluronic acid (HA) technology, have reported positive results from the CINGAL® 13-02 study evaluating the safety of a repeat injection of Cingal for symptomatic relief of osteoarthritis (OA) of the knee. CINGAL combines the Company's proprietary cross-linked sodium hyaluronate (currently marketed as the single-injection viscosupplement MONOVISC®) with an FDA-approved steroid, triamcinolone hexacetonide. Earlier this year, Anika announced positive results from CINGAL 13-01, a randomized, double-blind, placebo-controlled Phase 3 study, which demonstrated the efficacy and safety of a single injection of CINGAL for treatment of pain caused by OA of the knee.
